Pricing Log in Create free account
Saturday 17 October 2026 Export BSX’s income statement to Excel — free account

Boston Scientific Corporation

BSX Healthcare Medical Devices

Boston Scientific Corporation’s revenue for fiscal 2025 (year ended December 2025) was $20.1 billion, up 19.9% from fiscal 2024. In the quarter to June 2026, revenue grew 7.53%, EPS grew 14.8%, free cash flow grew 13.3% and total debt rose 8.95%, each against the same quarter a year earlier. Member of the S&P 500; revenue growth for five consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.

44.39 0.25 +0.57%
Market cap
$64.0B
P/E
17.9×
Fwd P/E
17.8×
Dividend yield
—
F-score
7/9
Altman Z
5.41
Beneish M
−2.49
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios Filings 10-Q 10-K

Boston Scientific Corporation (BSX) SEC filings, changes and red flags

Red flags

Filings

Form Period Filed What it reports Flags
8-K Oct 1, 2026 5.02 Departure or appointment of directors or officers; 8.01 Other events; 9.01 Financial statements and exhibits Officer departure
8-K Sep 21, 2026 5.02 Departure or appointment of directors or officers
8-K Sep 7, 2026 1.05 Material cybersecurity incident
8-K Aug 26, 2026 8.01 Other events
10-Q Jun 30, 2026 P1I2: 11 added · 3 removed · 37 modified
P2I1A: no changes
8-K Jul 29, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Jul 21, 2026 2.05 Costs of exit or disposal activities
8-K May 18, 2026 8.01 Other events; 9.01 Financial statements and exhibits
8-K May 18, 2026 8.01 Other events; 9.01 Financial statements and exhibits
8-K Apr 30, 2026 5.03 Amendments to the articles or bylaws; change in fiscal year; 5.07 Submission of matters to a vote of security holders; 9.01 Financial statements and exhibits
10-Q Mar 31, 2026
8-K Apr 22, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Mar 28, 2026 8.01 Other events; 9.01 Financial statements and exhibits
8-K Feb 26, 2026 1.01 Entry into a material definitive agreement; 1.02 Termination of a material definitive agreement; 2.03 Creation of a direct financial obligation; 9.01 Financial statements and exhibits
8-K Feb 18, 2026 5.02 Departure or appointment of directors or officers; 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits
10-K Dec 31, 2025 1: 16 added · 131 removed · 36 modified
1A: 4 added · 8 removed · 58 modified
7: 16 added · 43 removed · 82 modified
8-K Feb 2, 2026 5.02 Departure or appointment of directors or officers
8-K Feb 4, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Jan 14, 2026 1.01 Entry into a material definitive agreement; 9.01 Financial statements and exhibits
8-K Jan 15, 2026 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
8-K Nov 18, 2025 5.02 Departure or appointment of directors or officers; 9.01 Financial statements and exhibits
10-Q Sep 30, 2025
8-K Oct 22, 2025 5.02 Departure or appointment of directors or officers
8-K Oct 22, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Aug 29, 2025 5.02 Departure or appointment of directors or officers
10-Q Jun 30, 2025
10-K Dec 31, 2024

From the company’s filings on sec.gov. Red flags are raised by rules over the filings’ own data and text; they are not investment advice.